A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Prior treatment

• Any known or suspected active infection at screening or baseline, or any major episode of infection requiring hospitalization or treatment with IV anti microbials within 8 weeks prior to and during screening or treatment with oral anti microbials within 2 weeks prior to and during screening

Other illness

• History of relapsing remitting or secondary progressive MS at screening
• History of cancer, including hematologic malignancy and solid tumors, within 10 years of screening
• Known presence of other neurologic disorders that could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
• History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)

Other

• Immunocompromised state

• Ages 18-55 years at time of screening
• Diagnosis of PPMS, in accordance with the revised McDonald criteria 2017
• Expanded disability status scale (EDSS) score at screening and baseline 3- 6.5, inclusive
• Score of ≥ 2.0 on the Functional Systems (FS) scale for the pyramidal system that was due to lower extremity findings at screening and baseline
• Documented MRI of brain with abnormalities consistent with MS
• Patients must be neurologically stable for at least 30 days prior to randomization and baseline assessments